Patents Assigned to Astraea Therapeutics, LLC
  • Patent number: 11827617
    Abstract: The present invention provides novel piperidinyl-containing nociceptin receptor ligand compounds and pharmaceutical compositions useful in the treatment of neurological diseases and conditions where such ligands mediate the negative effects of the condition. Such neurological diseases and conditions include acute and chronic pain, substance abuse/dependence, alcohol addiction, anxiety, depression, sleep disorders, gastrointestinal disorders, renal disorders, cardiovascular disorders and Parkinson's disease.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: November 28, 2023
    Assignee: Astraea Therapeutics, LLC
    Inventors: Nurulain Zaveri, V. Blair Journigan
  • Patent number: 10358432
    Abstract: The present invention provides novel piperidinyl-containing nociceptin receptor ligand compounds and pharmaceutical compositions useful in the treatment of neurological diseases and conditions where such ligands mediate the negative effects of the condition. Such neurological diseases and conditions include acute and chronic pain, substance abuse/dependence, alcohol addiction, anxiety, depression, sleep disorders, gastrointestinal disorders, renal disorders, cardiovascular disorders and Parkinson's disease.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: July 23, 2019
    Assignee: Astraea Therapeutics, LLC
    Inventors: Nurulain Zaveri, Dennis Yasuda
  • Patent number: 9670198
    Abstract: Provided herein are novel and selective high affinity ?3?4 nicotinic acetycholine receptor ligands and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, drug addiction or pain using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of selectively antagonizing receptors such as, for example, the ?3?4 nicotinic acetycholine receptor using the compounds and compositions disclosed herein.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: June 6, 2017
    Assignee: Astraea Therapeutics, LLC
    Inventors: Nurulain Zaveri, Faming Jiang
  • Patent number: 9062042
    Abstract: Provided herein are novel and selective high affinity ?3?4 nicotinic acetylcholine receptor ligands and pharmaceutical compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, drug addiction or pain using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods for modulating a nicotinic acetylcholine receptor (nAChR). In still other embodiments, provided herein are methods of selectively antagonizing receptors such as, for example, the ?3?4 nicotinic acetylcholine receptor using the compounds and compositions disclosed herein.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: June 23, 2015
    Assignee: Astraea Therapeutics, LLC
    Inventors: Nurulain T. Zaveri, Faming Jiang
  • Publication number: 20140171466
    Abstract: The present invention relates to a method for the management of pain associated with sickle cell disease. In particular, the method comprises administering to a patient in need of such pain management a therapeutically effective amount of a nociceptin (NOP) receptor agonist or an NOP receptor agonist/mu opioid receptor (MOR) partial agonist.
    Type: Application
    Filed: August 14, 2013
    Publication date: June 19, 2014
    Applicants: Regents of the University of Minnesota, Astraea Therapeutics, LLC
    Inventors: Nurulain T. ZAVERI, Kalpna GUPTA
  • Patent number: RE49825
    Abstract: The present invention provides novel piperidinyl-containing nociceptin receptor ligand compounds and pharmaceutical compositions useful in the treatment of neurological diseases and conditions where such ligands mediate the negative effects of the condition. Such neurological diseases and conditions include acute and chronic pain, substance abuse/dependence, alcohol addiction, anxiety, depression, sleep disorders, gastrointestinal disorders, renal disorders, cardiovascular disorders and Parkinson's disease.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: February 6, 2024
    Assignee: Astraea Therapeutics, LLC
    Inventors: Nurulain Zaveri, Michael Meyer